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Review
Methods to Induce Chronic Ocular
Hypertension: Reliable Rodent Models as
a Platform for Cell Transplantation and
Other Therapies
Ashim Dey1, Abby L. Manthey2, Kin Chiu2,3,4, and Chi-Wai Do1
Abstract
Glaucoma, a form of progressive optic neuropathy, is the second leading cause of blindness worldwide. Being a prominent
disease affecting vision, substantial efforts are being made to better understand glaucoma pathogenesis and to develop novel
treatment options including neuroprotective and neuroregenerative approaches. Cell transplantation has the potential to play
a neuroprotective and/or neuroregenerative role for various ocular cell types (e.g., retinal cells, trabecular meshwork).
Notably, glaucoma is often associated with elevated intraocular pressure, and over the past 2 decades, several rodent models
of chronic ocular hypertension (COH) have been developed that reflect these changes in pressure. However, the underlying
pathophysiology of glaucoma in these models and how they compare to the human condition remains unclear. This limitation
is the primary barrier for using rodent models to develop novel therapies to manage glaucoma and glaucoma-related blindness.
Here, we review the current techniques used to induce COH-related glaucoma in various rodent models, focusing on the
strengths and weaknesses of the each, in order to provide a more complete understanding of how these models can be best
utilized. To so do, we have separated them based on the target tissue (pre-trabecular, trabecular, and post-trabecular) in
order to provide the reader with an encompassing reference describing the most appropriate rodent COH models for their
research. We begin with an initial overview of the current use of these models in the evaluation of cell transplantation
therapies.
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Introduction
Glaucoma is physiologically characterized by elevated
intraocular pressure (IOP), progressive retinal ganglion cell
(RGC) death, loss of RGC axons, optic nerve excavation,
and visual field loss that can lead to irreversible blindness1.
Although elevated IOP is considered the major risk factor2–5,
progressive loss of the RGCs has been shown to continue
even when the IOP is adequately controlled via medication
or surgery6,7. To better understand the glaucomatous RGC
degeneration, a large body of research has focused on the
pathophysiological mechanisms thought to be involved,
including the role of increased oxidative stress and free radi-
cals, the release of neurotransmitters (e.g., nitric oxide and
glutamate), the depletion of neurotrophins and growth fac-
tors, and the initiation of apoptosis8–13. There has also been
increased interest in the use of cell transplantation therapeu-
tics to treat these mechanisms via a single intervention
(e.g., cell graft) which could provide long-lasting protection
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during glaucoma pathogenesis or other chronic ocular dis-
eases14–16. Indeed, several preclinical studies have reported
positive outcomes using cell transplantation in animal glau-
coma models. For example, implantation of bone marrow
mesenchymal stem cells (BM-MSCs) reduces IOP in a
chronic ocular hypertension (COH) rodent model in addition
to significantly enhancing the survival of RGCs compared to
the control animals17. Similarly, implantation of induced
pluripotent stem cells in the anterior chamber (AC) of
4-mo-old transgenic-Y437H myocilin mutant mice (Tg-
MYOCY437H) has been shown to restore trabecular mesh-
work (TM) function and stabilize IOP as well as increase
RGC survival compared to control animals for 9 wk post-
implantation18. Several other studies have also reported neu-
roprotective effects following intravitreal injection of BM-
MSCs in a number of inducible COH rodent models, includ-
ing models using laser treatment19,20, hyaluronic acid (HA)
injection21, and intra-cameral injections of transforming
growth factor-b1 (TGF-b) for 0 to 35 d22. Intravitreal injec-
tion of dental pulp stem cells also appears to protect struc-
tural and functional loss of RGCs in induced COH rodent
glaucoma22 as well as in a rodent axotomy model23. Apart
from the injection of pluripotent and/or mesenchymal cells,
other cell transplantation therapies involving glucagon-like
peptide-1 have also been shown to protect RGCs and their
axons in an optic nerve crush model24. These studies indicate
that cell transplantation has the potential to play a favorable
hypotensive and neuroprotective role against glaucoma by
reducing IOP, enhancing RGC survival and outgrowth, and/
or altering the RGC microenvironment. While development
of neuroprotective and/or neuroregenerative therapeutic
strategies is an essential avenue of research, the majority
of these treatments have not yet been tested in clinical or
preclinical studies. Fortunately, various animal models have
been established that mimic the ocular changes associated
with glaucoma25–27, allowing investigation of the underlying
pathophysiology of this disease and the testing of treatment
efficacy.
While the anatomy and physiology of rodent eyes differ
in some ways to human eyes28–30, inducible rodent systems
are preferred for several reasons, including the ethics of their
experimental use, shorter life span, and cost-effective-
ness29,31–37. It has been suggested that the conventional out-
flow pathway in the mouse eye is similar to that of primate
eye as it has a continuous Schlemm’s canal and lamellated
TM38. Furthermore, the changes observed during human
glaucoma can also be reasonably mimicked in rodents. This
seems to be particularly true in regard to the lamina cribrosa
changes in the glaucomatous optic nerve head28. The aqu-
eous humor is produced by the ciliary body in the rat eye,
flows through the TM, and is collected in Schlemm’s canal
located in the angle of the AC in a manner similar to that
Figure 1. Schematic diagram illustrating the structure of whole eye (left) and anterior segment (right). During the conventional outflow
pathway, aqueous humor is produced by the ciliary body and it flows from the posterior chamber through the pupil into the anterior
chamber (shown by continuous lines with arrowheads). It then flows out through the trabecular meshwork into Schlemm’s canal and is
subsequently absorbed into the episcleral veins via the collector channels. In the unconventional outflow pathway, aqueous humor flows out
from anterior chamber through the face of the ciliary body and iris root to the ciliary muscle and suprachoroidal space to either veins in the
choroid and sclera or through scleral pores to episcleral tissue (shown by dashed lines and arrowheads).
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observed in humans31. The aqueous humor then enters the
venous plexus through collector channels in the limbal
region, allowing it to drain from the eye through the episcl-
eral drainage veins32. It is the dynamic balance of aqueous
humor inflow and outflow that effectively maintains physio-
logical IOP levels in both species (Figure 1).
In order to mimic the glaucoma-inducing changes in IOP,
various methods have been utilized to block the outflow of
aqueous humor in rodents25,26. Although a vast amount of
research using these models exists, very few articles have
directly compared the physiological attributes of these mod-
els to human glaucoma. In this review, we have summarized
the most prevalent experimental methods utilized to induce
COH in rodents, focusing on how they can be most effec-
tively used in translational research. This review can also
function as a guide for researchers to determine the appro-
priate glaucoma rodent model for their own research needs.
To this end, the methods described here can be classified into
3 primary groups: (Pre-TM), trabecular, and post- trabecular
(Post-TM) obstruction of the outflow39 as shown in Figure 1.
Pre-TM Models
AC Injection of Obstructive Substances
Outflow obstruction is often physically induced before the
aqueous humor passes through the TM. HA, microspheres/
microbeads, and magnetic microbeads have been used as
occlusion sources. Once injected into the AC, they cannot
pass through the TM due to their size and subsequently
impede outflow.
Injection of HA. HA is a naturally occurring glycosaminogly-
can polysaccharide that is widely distributed throughout the
human body in tissues such as the skin, cartilage, hair, and
eyes40. In the eye, HA is primarily localized to the aqueous
humor, vitreous humor, and TM, where it appears to play an
important role in the migration and maintenance of the
extracellular matrix40–42. Furthermore, this polysaccharide
also creates a gradient pressure between the AC and the
aqueous outflow pathways43. Thus, an optimal concentra-
tion of HA is required to maintain normal outflow levels
throughout the TM.
Interestingly, the concentration of HA in the aqueous
humor isolated from patients with primary open angle glau-
coma was found to be significantly lower (0.32 mg/mL) than
controls (0.61 to 2.56 mg/mL)44, whereas the concentration
in the aqueous humor of exfoliation subjects was signifi-
cantly higher (7.8 mg/mL) than controls45. In fact, it has been
noted that injection of HA during various intraocular sur-
geries, including cataract surgery46–48, appears to cause a
transient increase in IOP among 81% of operated eyes
(>10 mmHg)49.
The effect of HA on IOP has also been utilized to induce
changes in a number of animal models. Benozzi et al.50 were
the first to inject a 25 mL aliquot of HA (10 mg/mL) into the
AC of an anesthetized rat. In this study, 1 single injection
was found to raise the IOP 2-fold after 24 h, and this increase
sustained for 8 d. Weekly injection could also be used to
maintain the elevated IOP for up to 10 wk51. Notably, intra-
cameral HA injection also appears to cause a significant loss
of RGCs (40%) as well as functional changes compared with
the controls 10 wk after injection51.
Injection of latex microspheres. Microspheres are spherical
microbeads in the colloidal size range (diameter 0.02 to 15
mm) that are composed of an amorphous polymer such as
polystyrene. They can also be loaded with a variety of dyes
(e.g., fluorescein) that can be easily traced inside tissues via
fluorescence microscopy. In this way, microspheres have
been used for various experiments involving blood flow tra-
cing and drug delivery.
Weber and Zelenak52 were the first to use injected micro-
spheres to induce COH in the eyes of rhesus monkeys. Their
experiments were followed by those of Urcola et al.53 that
focused on using injected microspheres to similarly induce
COH in rat eyes. In these experiments, it appears that weekly
injections of 2 to 4  105 latex microspheres (diameter 10
mm) in 20 mL of a sterile aqueous solution (0.15 M NaCl,
0.02% Tween 20) into the AC using a 30-gauge needle
effectively blocked the TM, causing a subsequent elevation
in IOP. Similarly, a combination of 10 mL of microspheres (1
to 2 105) with 10 mL of 2% hydroxypropylmethylcellulose
(HPM) injected weekly into the AC also increases IOP, but
this increase occurs earlier (6 wk) compared with injections
of microspheres alone (9 wk) and can be sustained for 30 wk.
While mechanical obstruction itself is a simple process, it
remains unclear why there is a delay in the elevation of IOP.
Researchers have speculated that this phenomenon could be
due to species differences and/or the repeated use of general
anesthesia53. Notably, the peak IOP in both studies was
observed at week 27, when the IOP was 1.69-fold and
1.98-fold higher than the controls, respectively. Morpholo-
gically, loss of the RGCs was noted in 23.1%+ 2.1% of the
animals injected with microspheres alone, while 27.2% +
2.1% had RGC death in the microsphere and HPM group
after 24 wk of induced IOP elevation53.
More recently, Sappington et al.54 also used polystyrene
microbeads to block the TM and produce COH in both
brown Norway rats and C57BL/6 mice. In the rats, 15-mm-
diameter polystyrene microbeads were injected at a concen-
tration of 1  106 beads/mL via micropipette in volumes
ranging from 2.5 to 7 mL in order to evaluate the effect of
volume on elevated IOP. Single injections of these microbe-
ads were observed to induce a 21% to 34% increase in IOP
compared to the controls within the first 2 wk. An additional
injection after this initial 2 wk was also shown to maintain
this IOP increase for an additional 6 wk. Notably, there was a
significant difference in the induced IOP in the rat eyes after
injection of 2.5, 5, and 7 mL, with the 2 higher injection
volumes producing similar elevations in IOP. In the mice,
a 1 mL volume of 15 mm diameter microbeads injected into
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the AC was observed to produce a 30% increase in IOP
compared with the controls and persisted for at least 3 wk.
There was also a significant loss of axons and induced gliosis
along with degeneration and disorganization of the optic
nerve in both rats and mice 4 to 5 wk after the initial injec-
tion. Recent experiments conducted by Cone-Kimball
et al.55 also highlighted the effects of mouse strain on IOP
elevation post-microbead injection, indicating that this tech-
nique involves a high level of variability depending on
genetic background, injection volume, and so on.
Injection of paramagnetic microspheres. Unlike latex micro-
spheres, paramagnetic microspheres are typically composed
of polystyrene and uniformly coated with a biocompatible
ferrosoferric oxide complex that allows them to respond to a
magnet or magnetic field. Following exposure to a magnetic
field, these particles retain their magnetic properties and can
be demagnetized and remagnetized repeatedly and reprodu-
cibly. Paramagnetic microspheres have also been shown to
be nontoxic and do not have any associated systemic side
effects56. Thus, these particles are ideal for drug delivery,
whereby various medicines can be enclosed in the polystyr-
ene bead, injected into the blood stream, and effectively
directed to the target site with the help of a magnet.
In addition to drug delivery, Samsel et al.57 have used this
technique to evenly distribute the microbeads into the AC of
rats to consistently induce COH. With this method, 10 to 20
mL aliquots of 30 mg/mL ferromagnetic microspheres (5 mm
in diameter) are injected into the AC with a 30-gauge needle.
After injection, the microbeads can be spread evenly around
the iridocorneal angle from the site of injection with a mag-
net. Using this technique, a single injection was observed to
induce a sustained increase in IOP greater than 5 mmHg for
12 d, while 3 injections resulted in 6 wk of prolonged IOP
elevation and a 36% loss of RGCs. A similar study using the
same model reported axonal loss (80%) 4 wk after injection,
a result which may reflect a more acute insult to the retina
rather than COH58. Recently, Bunker et al.59 used a modified
version of this procedure using a circular magnet placed
around the rat eye prior to injection of the magnetic microbe-
ads (diameter 8.0 mm). Using this technique, they observed
an even distribution of microbeads around the iridocorneal
angle as well as a sustained increase in IOP (40.5 + 2.8
mmHg) compared to control eyes (19.7 + 0.3 mmHg) for
18 d after a single injection. This increase also caused a
subsequent change in RGC death, with the level of apoptosis
increasing approximately 15-fold compared with the
controls59.
General Points Concerning Pre-TM Models
Each of these pre-trabecular obstruction methods is inexpen-
sive, easy to perform, and temporarily blocks the TM to
increase IOP. They have been used extensively for evaluat-
ing drug delivery and to investigate changes in outflow and
IOP. Furthermore, these methods also have minimal
ischemia associated with them, as they do not block blood
flow to or from the eye. However, although useful and effec-
tive, multiple injections are needed in order to sustain a
higher IOP, which is both time and labor intensive. This need
for multiple injections stems from the basic concept of phys-
ical obstruction to induce COH, whereby the beads get stuck
in the intracellular spaces of the TM causing impairment of
aqueous humor outflow and increased IOP. However, for
these effects to be considered chronic, the obstruction is by
nature transient, with small clumps of the microspheres gath-
ering to gradually obstruct drainage. This necessitates the
use of multiple injections in order to produce a sustained
increase in IOP. Furthermore, elevation of IOP also causes
widening of the paracellular spaces, which may increase the
space between the cells allowing greater aqueous humor
outflow and flow through of the beads themselves. Hence,
additional beads are required to completely block the TM52.
These issues with retaining the obstructive substance, be it
beads or HA, after injection may also result in variable or
inconsistent changes in IOP, which may limit the practical
use of these models. In fact, several studies using microbeads
to induce COH reported that the diameter and volume
injected into the AC significantly influences the resulting
change in IOP. Thus, several researchers have tried to mini-
mize the effects of these variables by using viscous sub-
stances and/or different compositions of bead size (Table 1).
Moreover, in addition to being time and labor intensive,
multiple injections increase the chance of infection and pos-
sible downstream changes in ocular function not associated
with COH. Indeed, multiple injections increase the likeli-
hood of injury to the cornea, lens, and retina as well as
changes in aqueous-vitreous or blood–ocular barrier integ-
rity66. Moreover, the localization of the obstruction within
the AC is also difficult to control. For example, if beads
aggregate in the pupillary zone, they can obscure the visual
axis, compromise fundoscopic monitoring of optic nerve
damage, or cause leakage of the substance into the eye.
Taken together, while these pre-trabecular models have a
number of advantages, additional work may be necessary to
develop consistent results for preclinical trials.
TM Models
Laser Treatments
Unlike the pre-trabecular methods, laser photocoagulation
(LPC) blocks the outflow of the aqueous humor by destroy-
ing the TM tissue itself, and TM tissues can be burned using
an argon laser to induce COH67. Lasers are forms of light
that can hold a huge amount of energy, which in this context
are focused to burn the target tissues. Argon lasers, for exam-
ple, have a spectral range with emission peaks at wave-
lengths within the visible light range (488 and 514 nm)
and have been extensively used for the treatment of various
ocular diseases, including diabetic retinopathy, glaucoma,
and premacular hemorrhage68.
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COH induced by LPC of the TM was first demonstrated
in rats by Ueda et al.69. They injected 0.05 mL of Indian ink
into the AC of rat eyes with a 30-gauge needle 1 wk prior to
laser treatment. Indian ink consists of carbon particles which
stick to the TM, creating a 0.2 mm wide black band in the
limbal area. Then, when a 250 mW power laser is focused
for 0.2 s (0.5 mm spot size) directly on the black band, the
small carbon particles absorb the heat of laser and effectively
damage/scar the TM. This damage results in the subsequent
impairment of the aqueous outflow and a sustained increase
in IOP for 4 wk following 3 consecutive laser treatments
performed in 7 d intervals. Notably, the IOP was observed
to decrease once the laser treatments were stopped. In addi-
tion to altering IOP, this method also produced glaucoma-
tous optic nerve changes, including thinning of the nerve
fiber layer, reduction of axons, and degeneration of the optic
nerve. Ink injection alone did not affect IOP and was natu-
rally eliminated from the tissue by 12 wk postinjection69.
Using similar methods, Park et al.70 reported a 47% increase
in IOP and a 51% loss of RGCs compared to contralateral
eyes after 8 wk of laser treatments in Wistar rats.
Levkovitch-Verbin et al.71 have also evaluated laser-
induced changes in multiple ocular tissues, focusing on the
TM with or without additional damage to the episcleral
veins, in Wistar rats. They reported that TM-only laser treat-
ments cause a significant increase in IOP and loss of RGCs
(approximately 49%) after 9 wk. However, 76% of the eyes
required an additional laser treatment on the TM to increas-
ing the IOP significantly compared to controls. Their work is
further discussed in the post-TM models section.
To establish a similar laser-induced COHmodel in mice,
various methods have been evaluated. For example, Aihara
et al.72 and Mabuchi et al.73 previously demonstrated the
applicability of this model for inducing COH in Black
Swiss mice. In these studies, the mouse pupil was dilated
with topical mydriasis, and the aqueous humor was aspi-
rated to flatten the AC, bringing the root of iris closer to the
peripheral cornea. Then, LPC was applied to the limbal
area with a diode laser system (532 nm) to achieve angle
closure (peripheral anterior synechia). This method pro-
duced a 1.3-fold rise in IOP for 6 wk after a single laser
treatment. Compared to the contralateral eye, there was
also a significant decrease in the optic nerve cross-
sectional area (28%), mean axonal density (58%), and total
number of axons (63%).
Viral Vector Treatment
Another emerging method for increased IOP in rodent mod-
els is the use of viral vectors, whereby injection into the AC
or vitreous cavity results in viral gene transfer leading to the
impairment of aqueous outflow and increased IOP74. She-
pard et al.75 have reported that a single intravitreal or intra-
cameral injection of a viral vector containing human TGF-2
into rat (5 mL) or mouse (2 mL) eyes caused a significant
increase in IOP. This significant increase was noted after 4 d
of injection and was maintained for 12 d in rat eyes and 29 d
in mouse eyes compared to their respective controls. Inter-
estingly, the authors also observed that intravitreal injection
in mice caused a prolonged effect compared to intracameral
injection. Similarly, Buie et al.76 reported a sustained 48 d
increase in IOP following single intracameral injection of
bone morphogenetic protein 2 in the eyes of Brown-Norway
and Wistar rats which caused 31% to 34% loss of RGCs
compared to the controls after 29 d of injection.
General Points Concerning TM Models
Although laser-induced destruction of the TM (Table 2) has
many advantages, it also has various limitations. For exam-
ple, laser treatment can alter TM pigmentation and repeated
application may also prompt other complications, including
dryness, corneal opacity, and cataract formation. These
changes may in turn affect the technical aspects of the pro-
cedures, imaging quality, experimental outcomes, and/or
cause higher mortality rates in the animals. Furthermore, one
of the primary drawbacks of the LPCmethods described here
is that they require perforation of the cornea, which can
increase the chances of infection and may affect IOP mea-
surements made using tonometer devices as the corneal para-
meters are altered. Additionally, flattening of the AC can
also cause variability in the IOP, possibly limiting the sig-
nificance of the experiments.
As mentioned earlier, for the LPC TM model, trapped
carbon particles are used to damage the tissue; however, they
do not increase IOP alone and disappear 12 wk after Indian
ink injection69. These carbon particles form a cellular debris
material that, when a laser is applied, creates a transient pseu-
domembrane on the trabecular spaces. As noted, the IOP
decreases after laser treatments are stopped. However, the
mechanism underlying this normalization of pressure is still
elusive. One possible reason may be related to a decrease in
cellular debris material and the occurrence of endothelial cell
proliferation on the scarred TM tissue resulting in recovery of
aqueous outflow88. Studies have also reported that laser burn
induces an increase in TM cell division, resulting in the upre-
gulation of repair processes that could repopulate the TM and
recover function89,90. Additional work is warranted to better
understand this phenomenon.
It should also be noted that TMmethods are not suggested
for albino rodents, as they do not have pigmented TM. How-
ever, several researchers have established an alternative
rodent COH model by applying laser destruction at the post-
trabecular level (discussed below; Table 2) which can be
performed in albino rodents. Viral vector treatment may also
be a better alternative for these animals. The elevation of
IOP after viral vector injections seems to be dependent on
method of injection, animal strain, and age. Unfortunately,
injection of these vectors has been reported to cause ocular
inflammation which may affect the outcome75. These meth-
ods also need specialized equipment and training for han-
dling, making them more expensive.
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Post-TM Models
Another common area of the eye involved in balancing aqu-
eous inflow and outflow that can be obstructed to increase
IOP is the region posterior to the TM, particularly the episcl-
eral veins. For post-trabecular COH models, a number of
different methods have been developed and validated to
impede the episcleral venous pathway.
Laser Treatments
While LPC is commonly used as a trabecular model of COH
(as described above), WoldeMussie et al.78 induced COH in
rats by directly applying the argon laser to the limbal and
episcleral vessels without interfering with the TM. In this
model, LPC is performed on the veins approximately 0.5 to
0.8 mm away from the limbus as well as the episcleral drai-
nage veins. After 2 consecutive laser treatments within a 1
wk interval, the IOP was observed to increase 2-fold com-
pared to normal and remained at this level for 2 mo, resulting
in a 44.2% loss of the RGCs. Further, the immunoreactivity
of the intermediate filament glial fibrillary acidic protein
(GFAP) was also increased in the Mu¨ller cells after 3 wk
of induced hypertension. Various studies using this COH
rodent model have also reported structural and functional
changes similar to those observed in human glaucoma81–83.
The effects of LPC on IOP were further evaluated by
Levkovitch-Verbin et al.71. As described in the TM model
section, in this study, a diode laser (532 nm) was used on
various combinations of tissues, including the TM with the
episcleral veins, the TM only, or the limbal and perilimbal
veins only. With the exception of the limbal veins–only
group, the elevated IOP was sustained for approximately 3
wk. A repeated laser treatment was also performed 1 wk
after the first laser treatment for the eyes where the increase
in IOP was less than 6 mmHg. In this experiment, the mean
IOP after 6 wk for the combined group and TM group was
25.5 + 2.9 mmHg and 22.0 + 1.8 mmHg, respectively.
Axonal loss was significantly increased with respect to the
duration of increased IOP. In fact, in the combined group,
the axonal loss was 16.1%+ 14.4% after 1 wk (P ¼ 0.01),
59.7%+ 25.7% after 6 wk (P < 0.001), and 70.9%+ 23.6%
after 9 wk (P < 0.001). In contrast, the mean axonal loss for
the TM-only group was 19.1% + 14.0% after 3 wk (P ¼
0.004), 24.3%+ 20.2% after 6 wk (P < 0.001), and 48.4%
+ 32.8% after 9 wk (P < 0.001).
In order to increase the local photocoagulative effect of
diode laser (810 nm) treatment, Grozdanic et al.77 injected
10 mL of photosensitive dye (10 mg/mL indocyanine green)
into the AC of C57/BL6 mice 20 min prior to laser exposure
and induction of COH. A significant, sustained increase in
IOP was detected in the first 6 wk in 88% of the laser-treated
eyes, which subsequently returned to normal levels after 8
wk. Notably, this study also detected a significant loss of
RGCs, thinning of the retina, and degeneration of the optic
nerve 8 wk after LPC, all of which appear to be associated
with a notable decrease in retinal function (i.e., the electro-
retinogram [ERG] responses). It is important to mention that
these authors also administered topical pilocarpine 20 min
prior to laser treatment to induce pupil miosis, which serves
to protect the posterior pigmented structures of the eye from
the diode laser energy during application of the laser to the
TM and limbal veins.
To overcome the need for indocyanine green injection,
Gross et al.87 utilized an argon laser to damage the episcleral
and limbal veins all around the eye to induce COH in mice,
similar to a previous study using rats78. This mouse model
does not require corneal perforation and successfully ele-
vated the IOP by 1.5-fold in 90% of the treated eyes, result-
ing in the loss of 23% of the RGCs by 4 wk compared to the
untreated eyes. Similarly, Ji et al.86 induced COH in mice by
LPC of the limbal and episcleral veins. In doing so, they
demonstrated that a single intervention of laser treatment
can increase IOP by 7 mmHg, from a baseline of 13.0 +
1.8 mmHg to 20.0+ 2.8 mmHg. This increase sustained for
8 wk (17.0 + 2.2 mmHg) and was associated with a 27%
loss of RGCs after 4 wk86.
Cauterization/Ligation of Episcleral Veins
Models utilizing cauterization. One of the earliest rat COH
models for glaucoma research was the cauterization model,
which was first demonstrated by Shareef et al.91, hence being
designated the Shareef–Sharma model. This model involves
cauterizing the episcleral veins (1 or multiple veins) in
anesthetized rats with an ophthalmic cautery followed by
exposure of the veins via incisions in the conjunctiva. Impor-
tantly, when using this method, care must be taken to mini-
mize the damage to the surrounding conjunctiva and
underlying sclera. When performed properly, this method
produces a significant increase in IOP that is correlated with
the number of cauterized veins. In fact, while single vein
cauterization does not appear to significantly affect IOP,
researchers observed a 1.5-fold elevation in IOP when 2
veins were cauterized that was maintained for at least 1.5
mo postsurgery. An IOP elevation of 1.9-fold for 2.5 mo was
observed following the cauterization of 3 veins. The highest
elevation (4.5-fold) was shown to occur after 1.5 wk in rats
with 4 cauterized veins; however, cauterizing this number of
veins also caused profound ocular complications, including
proptosis, corneal edema, exposure keratopathy, and catar-
act, which were not observed in rats with fewer veins cau-
terized91. Histological analysis also showed that the level of
RGC death in these rats was directly proportional to the
increase in IOP as well as the duration of this increase92.
Similarly, Sawada and Neufeld93 showed an increase in IOP
(1.6-fold) over a 6-mo period following cauterization of 3
veins. This increase was shown to cause cupping of the optic
nerve head associated with a 40% loss of RGCs in the per-
ipheral retina. Interestingly, the loss of RGCs per week was
estimated to be 1.4% in the peripheral retina, but only 0.3%
in the central retina, indicating that glaucoma-related vision
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loss may be primarily due to the loss of cell function in the
peripheral regions of this tissue.
A previous study by Mittag et al.94 reported that cauter-
ization of 3 veins resulted in an increase in IOP that lasted for
15 d, while repeated (4 to 5 times) injection of 5-fluorouracil,
an antimetabolic agent that disrupts angiogenesis, in 3 to 4 d
intervals after vein cauterization sustained this elevated IOP
for at least 12 wk. This observation suggests that the growth
of new vessels may result in increased episcleral venous
patency. An electrophysiology study also showed that this
technique can damage the photoreceptor cells as well as the
bipolar cells, as the amplitude of both the a-wave and b-wave
in their ERG analysis was significantly reduced in treated
eyes compared to controls95. The above findings suggest that
the damage to the outer retinal layer may be due to ischemia
in the tissue, which may limit the ability of this model to
mimic human glaucoma94,95.
While many cauterization models have used rats as a
model, a mouse model has also been established. While
cauterizing the episcleral veins in mice is more difficult
because of their small size, Ruiz-Ederra and Verkman96
were able to induce COH in albino cluster of differentiation
1 (CD1) mice. In fact, IOP was elevated in 87% of the treated
eyes for 4 wk and was associated with a 20% loss of RGCs
following a second round of cauterization (2 wk after the
first treatment). However, in this study, one-third of the
operated eyes were excluded due to surgery-related compli-
cations, such as vein leakage as well as conjunctiva and
scleral tissue damage. In mice, it also appears that cauteriza-
tion of 2 veins had no significant prolonged effect on the
IOP, meaning that 3 or more veins would need to be operated
on, which increases the chance of ocular damage and
complications96.
Models utilizing ligation. Ligation, similar in some ways to
cauterization, is performed by suturing the episcleral veins
to block the venous outflow. Notably, ligation of 3 episcleral
veins has been shown to induce COH in adult rabbits. More
recently, Yu et al.97 demonstrated COH in female Wistar rats
following ligation of 3 episcleral veins unilaterally with a 10/
0 nylon suture after dissecting the overlying conjunctiva and
Tenon’s capsule. This method produced a sustained increase
in IOP (24.5 + 2.3 mmHg in operated eyes compared to
19.7 + 1.9 mmHg in control eyes) for 7 mo in 40% of the
treated eyes. This prolonged elevation of IOP caused optic
disc cupping and a 35% loss of RGCs in 8 mo following the
ligation. Although this method is relatively inexpensive, it
requires excellent microsurgical skills in order to perform
the ligation on the miniscule episcleral veins and treated eyes
often (59.2%) require religation to elevate the IOP.
Ligation methods have also been established to induce
COH in mice. For example, ligation of 3 to 5 veins over a
300 area using 11-0 nylon sutures was shown to cause COH
in C57B1/6J mice98. This method produced a sustained ele-
vation in IOP (approximately 19 mmHg) for 10 wk com-
pared to unoperated eyes (approximately 11 mmHg) and
caused a 30% decrease in viable RGCs. Notably, repeated
surgeries at 1 wk intervals were needed for the eyes that did
not have a measurable elevation in IOP initially.
Intraepiscleral Vein Injection with Hypertonic Saline
Another well-established posttrabecular obstruction method
is the Moore–Morrison model99, whereby COH is induced in
a rat via cannulation of an aqueous vein with a 50-mm glass
microneedle followed by injection of a concentrated saline
solution (2 M). Injection of this hypertonic solution was
demonstrated to cause optic disc cupping, selective loss of
RGCs, disorganization of the nerve fibers at the level of the
lamina cribrosa, and loss of optic nerve axons. Furthermore,
injection of saline into one of the radial episcleral veins also
appears to cause sclerosis of the TM, which impedes AH
outflow and raises IOP. This method involves placement
of a polypropylene ring (C shaped) around the equator of
the eye in the anesthetized rat which temporarily occludes or
creates pressure in all of the episcleral veins except the one
to which hypertonic saline is injected. The plastic ring is
removed following injection of 50 mL of sodium chloride
(approximately 1.75 M) into the vein. This procedure drives
the hypertonic saline from the site of injection into the TM
and AC through Schlemm’s canal after being injected into
the exposed vein using a borosilicate glass microneedle. As a
result, the IOP was shown to increase in the first 7 to 10 d
and sustained for an extended period (200 d)100. This
increase occurred in approximately 60% of treated eyes and
ranged from 10 to 35 mmHg above baseline levels99,101.
Notably, the variability in IOP elevation likely reflects the
variability in the extent of sclerosis of the TM tissues fol-
lowing the saline injection. In fact, a second injection into
another vein 180 away from the first vein was often needed
in order to successfully induce elevation of the IOP. How-
ever, once an increase in IOP was observed, structural and
functional changes in the retina were also detected, including
RGC loss (39% to 93%), axon loss, extracellular matrix
protein deposition at the optic nerve head, and progressive
excavation of the optic disc, similar to other COH models.
Fortune et al.102 also reported a 50% reduction in the positive
scotopic threshold response (pSTR) after 5 wk of induced
COH among Brown-Norway rats using this model. Interest-
ingly, the functional and structural changes in this model
appear to be significantly correlated with the extent of ele-
vated IOP, but not with the duration of this increase103. A
recent study also reported an upregulation of inflammatory
response signals and reorientation of the astrocytes in the
optic nerve head in response to the elevated IOP104. Alter-
natively, Morrison et al.105 focused primarily on the effect of
hypertonic saline concentration (from 1.6 to 2.0 M) on IOP.
In doing so, they revealed that the higher concentration (>2.0
M) caused more destruction in the TM along with a higher
increase in IOP that lasted for several months. However,
injection of these higher concentrations of saline also
appears to cause excessive inflammation and ciliary body
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damage. Hence, a concentration of 1.74 M has become the
standard for use in most rodent COH models of this variety.
Similar to the rat hypertonic saline–injected COH model,
McKinnon et al.106 also induced COH in C57BL/6 mice by
injecting hypertonic saline (2.0 M) into an episcleral vein,
which resulted in a 20% decrease in viable RGCs. In another
study, 1.5 M saline was injected into C57BL/6 mouse eyes
and produced a sustained increase in IOP (10.0 + 3.3
mmHg) for at least 6 wk compared to controls (7.4 + 2.2
mmHg)107. However, in this study, 80% of the eyes required
repeated injection during the 2nd and 4th wk to sustain the
elevated IOP.
Circumlimbal Suture
Recently, a less invasive COH rat model was reported by Liu
et al.108, whereby an increase in IOP was induced in Long-
Evans rats using a circumlimbal suturing technique. Here, 8/
0 nylon suture was tied around the equator (approximately
1.5 mm behind the limbus) of the eye with 5 to 6 subcon-
junctival anchor points. Care was taken to avoid damage and
direct pressure over the episcleral veins. This method pro-
duced a 7 to 10 mmHg increase in IOP compared to the
baseline that lasted for 15 wk, resulting in progressive thin-
ning of the nerve fiber layer (approximately 40%). ERG
analysis also revealed a significant reduction in the ampli-
tude of the a-wave (10.8%), b-wave (9.0%), and pSTR
(26.7%) responses in the COH group. However, the reduc-
tion in photoreceptors and bipolar cells appeared to be stable
for 2 wk after suturing, whereas the response of the RGCs
(i.e., pSTR) progressively deteriorated from the 2nd to the
15th wk. Importantly, the suture material itself (untied) did
not affect the IOP, structural morphology of the retina, or the
ERG responses.
Technically, this method is relatively inexpensive and
temporary, as the induced COH can be reversed simply by
removing the suture. Furthermore, this method has less asso-
ciated risk in terms of the chances of infection, as it is less
invasive and only requires a single surgery. These attributes
make this model useful for evaluating the efficacy of drugs
aimed at reducing IOP as well as studies investigating neu-
roprotection for a longer time period. However, the extent of
the initial spike in IOP and the exact mechanism underlying
this increase in this model still remain unclear and further
investigation is necessary.
General Points Concerning Post-TM Models
The post-TM models mentioned here are the most com-
monly used to induce COH in rodents. However, direct com-
parison between these methods is difficult as the techniques
used for each are diverse, resulting in different levels and
duration of IOP elevation. Therefore, variability in the struc-
tural and functional losses correlated to IOP elevation among
these methods can be expected. Although they have their
differences, each of these post-trabecular obstruction
methods is relatively inexpensive but requires surgical
expertise in order to block the outflow drainage. They have
been used extensively for evaluating the effect of elevated
IOP, pathophysiology of glaucoma, and the neuroprotective
effects of new drugs. However, these methods also have
several limitations. For example, all post-trabecular methods
directly or indirectly cause a certain extent of retinal and/or
choroidal ischemia by blocking venous drainage. Therefore,
these models may not be suitable when evaluating the effi-
cacy of a drug which enhances the AH outflow facility to
reduce IOP. In addition, angiogenesis-related mechanisms
appear to be upregulated in the ocular vessels, which subse-
quently promote neovascularization and may also alter the
pathophysiology of glaucoma by activating downstream pro-
tective mechanisms in the retinal neurons.
Topical Application of Corticosteroids
Induced ocular hypertension is a well-known consequence of
steroid use among primates and nonprimate mammals, being
first reported by McLean et al.109 and Gordon et al.110. The
mechanism underlying this phenomenon was later described
by Francois and Victoria-Troncoso111, whereby they suggest
that steroids inhibit the activity of hyaluronidase, resulting in
the accumulation of mucopolysaccharides within the TM,
restricted aqueous outflow, and a subsequent increase in
IOP. These changes are thought to mimic the etiology of
primary open angle glaucoma in humans112. More recently,
similar steroid-induced changes in IOP have been documen-
ted in Wistar rats following the application of a topical ster-
oid (dexamethasone) 4 times per day for 4 wk. In this study,
a significant increase in IOP was noted after only 2 wk of
steroid application compared to the controls113. Topical
application of dexamethasone phosphate (0.1%) 3 times per
day also caused a significant increase in IOP (7.7 + 0.8
mmHg higher than control) in mouse eyes. This treatment
resulted in a 55% reduction in the amplitude of the pattern
ERG and a 16% decrease in viable RGCs after 20 wk of
treatment compared to the controls114.
Although this model is inexpensive and technically easy
to perform, the administration of steroids may introduce
other functional changes as steroid treatment has been shown
to facilitate neuroprotection as well as depression115,116.
Comparison of Induced COH with
Other Models
Transgenic Models
There are currently several transgenic rodent glaucoma mod-
els that have been developed and utilized to induce reprodu-
cible COH, including DBA/2J mice117, Col1a1r/r mice118,
Tyr423His Myoc mice119, Glutamate/aspartate-deficient
mice120, and Tg-MYCOY437H mice121. However, these
models have several limitations when compared with the
more common inducible COH rodent models. For example,
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transgenic rodents often only have mild to moderately ele-
vated IOP levels with anterior segment anomalies. This is
particularly true for the Col1a1r/r mice, which have signifi-
cantly higher IOP compared with the control mice at 18
(21% higher), 24 (44% higher), and 36 wk (36% higher) that
is associated with AC abnormalities that may affect the final
experimental outcome118. Furthermore, the time duration
needed for rodents to manifest a glaucoma phenotype (6 to
18 mo) is longer than that needed for the inducible models,
making these experiments more expensive, time-consuming,
and labor-intensive18. These transgenic rodents also develop
bilateral changes in IOP, thus another set of animals are
required for use as the experimental controls.
Acute Optic Nerve Trauma
The acute optic nerve trauma models currently used to
induce RGC death in rodents include various optic nerve
crush models as well as full thickness or partial axotomy
models122–124. Notably, these models are known to cause
apoptosis of all of the RGCs, with most of the cells dying
within the first 2 wk following the initial trauma. However,
these acute changes may or may not mimic those observed
during chronic diseases when the patient is exposed to an
insult for a relatively long period of time. Furthermore, dur-
ing human glaucoma, RGC death and optic nerve changes
are typically gradual. Thus, it is likely that the inducible
COH models described earlier can be used to mimic human
glaucoma more effectively than these acute optic nerve
trauma models.
Conclusions
Animal models of COH are useful tools for studying the
etiology of human glaucoma during disease onset and patho-
logical progression as well as the effect of therapies in a
controlled and reproducible manner. These models have
been extensively used to enhance our understanding of the
IOP-related changes observed in the eyes of glaucoma
patients and have clearly demonstrated the involvement of
COH in the morphological and functional damage that
occurs in their retinas. Importantly, when choosing the ideal
COH rodent model for a glaucoma study, researchers should
be aware of the various advantages and disadvantages of
each. Some general characteristics that should be preferred
are that the model is minimally invasive, inexpensive, and
easy to perform. Moreover, the model should be able to
produce a sustained elevation in IOP for a prolonged period
(>6 wk) that results in RGC death and loss of function with-
out interfering with the photoreceptors or other neurons in
the retina. Finally, no surgically induced complications, such
as intraocular bleeding, analysis obstruction (e.g., retinal
imaging), or damage to the optic nerve head, should occur.
Unfortunately, no single COH model currently in use incor-
porates all of these features.
While the present review is the first to compare these
specific methods (Table 3), others have previously
Table 3. Overview of Various Methods to Induce COH.
Level of Intervention Procedure Species
Specialized
Material/
Instruments Expertise Expense* References
Invasive Pre-trabecular HA injection Rat/mice Hyaluronic acid Micro surgery þ 50,51,125
Microbeads Rat/mice Microbeads þ 53–55,60–65
Magnetic microbeads Rat/mice Magnetic beads,
magnet
þ 57–59
Trabecular Viral vectors injection Rat/mice Viral vectors Micro surgery þþ 74–76
Laser on TM Rat/mice Laser machine Laser operation þþ 69,70,72,73
Post-trabecular Laser on limbal and
episcleral veins
Rat/mice Laser machine Laser operation þþ 71,78,81–83,86,87,80,84,85
Cauterization of
episcleral veins
Rat/mice Cautery Micro surgery þ 91–96,126–129
ligation of episcleral
veins
Rat/mice 10-0/11-0 nylon
suture
þ 97,98
Hypertonic saline
injection into
episcleral veins
Rat/mice Customized
plastic ring
þ 100–105,130
Circumlimbal suture Rat/mice 8-0 nylon suture þ 108
Combination of
Trabecular and post-
trabecular
Laser on TM þ
Episcleral veins
Rat/mice Laser machine Laser operation þþ 71,77
Noninvasive Topical corticosteroid Rat/mice Steroid drops NA NA 113,114,131–133
Abbreviations: COH, chronic ocular hypertension; TM, trabecular meshwork; NA, not applicable; þ, relatively mild expensive; þþ, relatively moderate to
high expensive.
*Relative expense.
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highlighted the similarities and differences among different
glaucoma models134–137. McKinnon et al.138, for instance,
compared the hypertonic saline injection model, cautery
models, and limbal laser (argon) model. In their analysis,
the laser-induced model appeared to produce the most repro-
ducible sustained elevation of IOP (occurring in 100% of the
animals compared to 42% and 49% for the hypertonic saline
and cautery models, respectively) but also appeared to cause
optic nerve damage in 83% while only 36% and 20% were
damaged for the other models. Similarly, Urcola et al.53 pre-
viously compared the cautery, injected microsphere, and
injected microsphere with HPM models, which produced
RGC death in 28.5% + 2.4%, 23.1% + 2.1%, and 27.2%
+ 2.1% of the animals, respectively. These other reviews,
much like the current analysis, largely recommend weighing
the advantages and disadvantages of each model before
designing the study. Unlike previous analyses, however,
we have provided a more thorough evaluation of these mod-
els based on the ocular tissue targeted (pre-trabecular, trabe-
cular, or post-trabecular). Furthermore, this review is
particularly relevant for researchers interested in using these
rodent models to investigate the use of various therapies,
such as cell transplantation. In fact, multiple cell transplan-
tation studies using a variety of cell types, including
mesenchymal stromal cells17,21,22 and pluripotent stem
cells18,139, have indicated that this technique may mediate
neuroprotection of the RGCs and help restore IOP regulatory
mechanisms during glaucoma18,139. Utilizing 1 or more of
the rodent models described here will further elucidate the
possible therapeutic applications of these treatments.
The future of glaucoma research will be fundamentally
based on the continual development of suitable COH mod-
els. These models are essential to advancing our understand-
ing of the physiological mechanisms functioning during
glaucoma onset and pathogenesis as well as for analyzing
novel glaucoma therapies. Additionally, there have also been
numerous advances in the technology used to assess glauco-
matous damage, including the measurement of IOP, RGC
death, optic nerve damage, and retinal function. Utilization
of these new technologies in basic science and biotechnol-
ogy studies will continue to lead to the development of better
translational glaucoma models and the subsequent enrich-
ment of patient treatment and care.
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